Do analysts prefer TMCI or HSAQ?

Treace Medical Concepts presently has a consensus price target of $5.17, indicating a potential upside of 30.89%. Given Treace Medical Concepts' stronger consensus rating and higher probable upside, research analysts clearly believe Treace Medical Concepts is more favorable than Health Sciences Acquisitions Co. 2. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Treace Medical Concepts 2 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.86 Health Sciences Acquisitions Co. 2 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, TMCI or HSAQ?

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Treace Medical Concepts. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Treace Medical Concepts $212.69M 1.21 -$59M -$0.93 N/A Health Sciences Acquisitions Co. 2 N/A N/A -$380K N/A N/A

Do analysts prefer ELMD or HSAQ?

Electromed presently has a consensus price target of $43.75, indicating a potential upside of 58.00%. Given Electromed's stronger consensus rating and higher possible upside, equities research analysts plainly believe Electromed is more favorable than Health Sciences Acquisitions Co. 2. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Electromed 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Health Sciences Acquisitions Co. 2 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, ELMD or HSAQ?

Electromed has higher revenue and earnings than Health Sciences Acquisitions Co. 2. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Electromed $73.78M 3.11 $5.15M $1.31 21.14 Health Sciences Acquisitions Co. 2 N/A N/A -$380K N/A N/A

Do analysts rate HSAQ or PROF?

Profound Medical has a consensus price target of $11.50, suggesting a potential upside of 66.67%. Given Profound Medical's stronger consensus rating and higher probable upside, analysts plainly believe Profound Medical is more favorable than Health Sciences Acquisitions Co. 2. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Health Sciences Acquisitions Co. 2 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Profound Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has better valuation & earnings, HSAQ or PROF?

Health Sciences Acquisitions Co. 2 has higher earnings, but lower revenue than Profound Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Health Sciences Acquisitions Co. 2 N/A N/A -$380K N/A N/A Profound Medical $16.10M 15.67 -$42.57M -$0.98 N/A

Do analysts recommend PDEX or HSAQ?

Pro-Dex currently has a consensus price target of $74.00, indicating a potential upside of 18.42%. Given Pro-Dex's stronger consensus rating and higher possible upside, research analysts plainly believe Pro-Dex is more favorable than Health Sciences Acquisitions Co. 2. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pro-Dex 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Health Sciences Acquisitions Co. 2 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, PDEX or HSAQ?

Pro-Dex has higher revenue and earnings than Health Sciences Acquisitions Co. 2. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pro-Dex $77.55M 2.60 $13.66M $4.13 15.13 Health Sciences Acquisitions Co. 2 N/A N/A -$380K N/A N/A

Do analysts rate STIM or HSAQ?

Neuronetics currently has a consensus target price of $4.67, suggesting a potential upside of 119.09%. Given Neuronetics' stronger consensus rating and higher probable upside, equities analysts clearly believe Neuronetics is more favorable than Health Sciences Acquisitions Co. 2. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuronetics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Health Sciences Acquisitions Co. 2 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, STIM or HSAQ?

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Neuronetics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neuronetics $155.10M 1.05 -$39M -$0.44 N/A Health Sciences Acquisitions Co. 2 N/A N/A -$380K N/A N/A

Health Sciences Acquisitions Co. 2 (HSAQ) Competitors

$5.95 +0.22 (+3.84%)

As of 10/9/2026

Compare

HSAQ vs. TMCI, ELMD, PROF, PDEX, and STIM

Should you buy Health Sciences Acquisitions Co. 2 stock or one of its competitors? Health Sciences Acquisitions Co. 2's main competitors and comparable companies include Treace Medical Concepts (TMCI), Electromed (ELMD), Profound Medical (PROF), Pro-Dex (PDEX), and Neuronetics (STIM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Health Sciences Acquisitions Co. 2 compare to Treace Medical Concepts?

Treace Medical Concepts (NASDAQ:TMCI) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Treace Medical Concepts has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Treace Medical Concepts.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Treace Medical Concepts	$212.69M	1.21	-$59M	-$0.93	N/A
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380K	N/A	N/A

84.1% of Treace Medical Concepts shares are owned by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 23.4% of Treace Medical Concepts shares are owned by insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Treace Medical Concepts had 1 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 1 mentions for Treace Medical Concepts and 0 mentions for Health Sciences Acquisitions Co. 2. Treace Medical Concepts' average media sentiment score of 0.89 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that Treace Medical Concepts is being referred to more favorably in the media.

Company	Overall Sentiment
Treace Medical Concepts	Positive
Health Sciences Acquisitions Co. 2	Neutral

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Treace Medical Concepts' net margin of -28.99%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Treace Medical Concepts' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Treace Medical Concepts	-28.99%	-71.37%	-30.49%
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%

Treace Medical Concepts presently has a consensus price target of $5.17, indicating a potential upside of 30.89%. Given Treace Medical Concepts' stronger consensus rating and higher probable upside, research analysts clearly believe Treace Medical Concepts is more favorable than Health Sciences Acquisitions Co. 2.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86
Health Sciences Acquisitions Co. 2	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Treace Medical Concepts beats Health Sciences Acquisitions Co. 2 on 8 of the 13 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Electromed?

Electromed (NYSE:ELMD) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

40.8% of Electromed shares are owned by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 11.0% of Electromed shares are owned by insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Electromed's average media sentiment score of 0.00 equaled Health Sciences Acquisitions Co. 2'saverage media sentiment score.

Company	Overall Sentiment
Electromed	Neutral
Health Sciences Acquisitions Co. 2	Neutral

Electromed presently has a consensus price target of $43.75, indicating a potential upside of 58.00%. Given Electromed's stronger consensus rating and higher possible upside, equities research analysts plainly believe Electromed is more favorable than Health Sciences Acquisitions Co. 2.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Health Sciences Acquisitions Co. 2	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Electromed has higher revenue and earnings than Health Sciences Acquisitions Co. 2.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$73.78M	3.11	$5.15M	$1.31	21.14
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380K	N/A	N/A

Electromed has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market.

Electromed has a net margin of 11.34% compared to Health Sciences Acquisitions Co. 2's net margin of 0.00%. Electromed's return on equity of 15.71% beat Health Sciences Acquisitions Co. 2's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%

Summary

Electromed beats Health Sciences Acquisitions Co. 2 on 9 of the 11 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Profound Medical?

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and Profound Medical (NASDAQ:PROF) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. Comparatively, 47.9% of Profound Medical shares are held by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are held by insiders. Comparatively, 1.5% of Profound Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Health Sciences Acquisitions Co. 2 has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market. Comparatively, Profound Medical has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market.

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Profound Medical's net margin of -171.57%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%
Profound Medical	-171.57%	-63.03%	-51.24%

In the previous week, Profound Medical had 14 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 14 mentions for Profound Medical and 0 mentions for Health Sciences Acquisitions Co. 2. Profound Medical's average media sentiment score of 0.35 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that Profound Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Health Sciences Acquisitions Co. 2	Neutral
Profound Medical	Neutral

Profound Medical has a consensus price target of $11.50, suggesting a potential upside of 66.67%. Given Profound Medical's stronger consensus rating and higher probable upside, analysts plainly believe Profound Medical is more favorable than Health Sciences Acquisitions Co. 2.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Sciences Acquisitions Co. 2	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Health Sciences Acquisitions Co. 2 has higher earnings, but lower revenue than Profound Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380K	N/A	N/A
Profound Medical	$16.10M	15.67	-$42.57M	-$0.98	N/A

Summary

Profound Medical beats Health Sciences Acquisitions Co. 2 on 8 of the 14 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Pro-Dex?

Pro-Dex (NASDAQ:PDEX) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

Pro-Dex has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market.

In the previous week, Pro-Dex had 2 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 2 mentions for Pro-Dex and 0 mentions for Health Sciences Acquisitions Co. 2. Pro-Dex's average media sentiment score of 0.91 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that Pro-Dex is being referred to more favorably in the media.

Company	Overall Sentiment
Pro-Dex	Positive
Health Sciences Acquisitions Co. 2	Neutral

Pro-Dex currently has a consensus price target of $74.00, indicating a potential upside of 18.42%. Given Pro-Dex's stronger consensus rating and higher possible upside, research analysts plainly believe Pro-Dex is more favorable than Health Sciences Acquisitions Co. 2.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
Health Sciences Acquisitions Co. 2	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Pro-Dex has higher revenue and earnings than Health Sciences Acquisitions Co. 2.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$77.55M	2.60	$13.66M	$4.13	15.13
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380K	N/A	N/A

Pro-Dex has a net margin of 17.62% compared to Health Sciences Acquisitions Co. 2's net margin of 0.00%. Pro-Dex's return on equity of 25.13% beat Health Sciences Acquisitions Co. 2's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	17.62%	25.13%	16.02%
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%

15.3% of Pro-Dex shares are owned by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 48.0% of Pro-Dex shares are owned by company insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Pro-Dex beats Health Sciences Acquisitions Co. 2 on 12 of the 14 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Neuronetics?

Neuronetics (NASDAQ:STIM) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

53.6% of Neuronetics shares are owned by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 8.4% of Neuronetics shares are owned by company insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Neuronetics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$155.10M	1.05	-$39M	-$0.44	N/A
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380K	N/A	N/A

In the previous week, Neuronetics had 3 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 3 mentions for Neuronetics and 0 mentions for Health Sciences Acquisitions Co. 2. Neuronetics' average media sentiment score of 0.94 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that Neuronetics is being referred to more favorably in the media.

Company	Overall Sentiment
Neuronetics	Positive
Health Sciences Acquisitions Co. 2	Neutral

Neuronetics has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market.

Neuronetics currently has a consensus target price of $4.67, suggesting a potential upside of 119.09%. Given Neuronetics' stronger consensus rating and higher probable upside, equities analysts clearly believe Neuronetics is more favorable than Health Sciences Acquisitions Co. 2.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Health Sciences Acquisitions Co. 2	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Neuronetics' net margin of -19.62%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-19.62%	-125.11%	-22.15%
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%

Summary

Neuronetics beats Health Sciences Acquisitions Co. 2 on 7 of the 13 factors compared between the two stocks.

Get Health Sciences Acquisitions Co. 2 News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HSAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HSAQ vs. The Competition

Export

Metric	Health Sciences Acquisitions Co. 2	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$66.71M	$5.49B	$7.25B	$13.28B
Dividend Yield	N/A	1.77%	2.52%	22.58%
P/E Ratio	N/A	25.57	275.59	26.13
Price / Sales	N/A	71.50	594.27	89.17
Price / Cash	N/A	32.56	27.30	36.12
Price / Book	-9.60	5.95	10.82	6.16
Net Income	-$380K	$146.14M	$3.50B	$381.12M
7 Day Performance	N/A	-0.58%	-1.19%	-1.43%
1 Month Performance	-2.78%	-2.13%	-4.00%	-3.36%
1 Year Performance	88.89%	5.39%	7.13%	1.49%

Health Sciences Acquisitions Co. 2 Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HSAQ Health Sciences Acquisitions Co. 2	N/A	$5.95 +3.8%	N/A	+88.9%	$66.71M	N/A	N/A	4
TMCI Treace Medical Concepts	3.0636 of 5 stars	$3.89 -2.8%	$5.17 +32.9%	-32.8%	$260.14M	$212.69M	N/A	450
ELMD Electromed	2.0135 of 5 stars	$28.20 -0.2%	$43.75 +55.1%	+14.9%	$233.69M	$73.78M	37.60	197
PROF Profound Medical	2.6827 of 5 stars	$5.68 -6.6%	$11.50 +102.5%	+17.5%	$222.30M	$16.10M	N/A	162	Trending News Analyst Upgrade High Trading Volume
PDEX Pro-Dex	4.4431 of 5 stars	$62.80 -3.3%	$74.00 +17.8%	+87.5%	$207.96M	$77.55M	15.21	206

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HSAQ) was last updated on 10/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Health Sciences Acquisitions Co. 2 (HSAQ) Competitors

HSAQ vs. TMCI, ELMD, PROF, PDEX, and STIM

How does Health Sciences Acquisitions Co. 2 compare to Treace Medical Concepts?

Summary

How does Health Sciences Acquisitions Co. 2 compare to Electromed?

Summary

How does Health Sciences Acquisitions Co. 2 compare to Profound Medical?

Summary

How does Health Sciences Acquisitions Co. 2 compare to Pro-Dex?

Summary

How does Health Sciences Acquisitions Co. 2 compare to Neuronetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSAQ vs. The Competition

Health Sciences Acquisitions Co. 2 Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Health Sciences Acquisitions Co. 2 (HSAQ) Competitors

HSAQ vs. TMCI, ELMD, PROF, PDEX, and STIM

How does Health Sciences Acquisitions Co. 2 compare to Treace Medical Concepts?

Which has more volatility & risk, TMCI or HSAQ?

Which has preferable valuation & earnings, TMCI or HSAQ?

Do institutionals & insiders believe in TMCI or HSAQ?

Does the media prefer TMCI or HSAQ?

Is TMCI or HSAQ more profitable?

Do analysts prefer TMCI or HSAQ?

Summary

How does Health Sciences Acquisitions Co. 2 compare to Electromed?

Do insiders and institutionals have more ownership in ELMD or HSAQ?

Does the media prefer ELMD or HSAQ?

Do analysts prefer ELMD or HSAQ?

Which has stronger valuation and earnings, ELMD or HSAQ?

Which has more volatility and risk, ELMD or HSAQ?

Is ELMD or HSAQ more profitable?

Summary

How does Health Sciences Acquisitions Co. 2 compare to Profound Medical?

Do insiders and institutionals have more ownership in HSAQ or PROF?

Which has more risk and volatility, HSAQ or PROF?

Is HSAQ or PROF more profitable?

Does the media favor HSAQ or PROF?

Do analysts rate HSAQ or PROF?

Which has better valuation & earnings, HSAQ or PROF?

Summary

How does Health Sciences Acquisitions Co. 2 compare to Pro-Dex?

Which has more volatility & risk, PDEX or HSAQ?

Does the media prefer PDEX or HSAQ?

Do analysts recommend PDEX or HSAQ?

Which has higher earnings & valuation, PDEX or HSAQ?

Is PDEX or HSAQ more profitable?

Do institutionals & insiders have more ownership in PDEX or HSAQ?

Summary

How does Health Sciences Acquisitions Co. 2 compare to Neuronetics?

Do institutionals and insiders hold more shares of STIM or HSAQ?

Which has better earnings & valuation, STIM or HSAQ?

Does the media prefer STIM or HSAQ?

Which has more risk & volatility, STIM or HSAQ?

Do analysts rate STIM or HSAQ?

Is STIM or HSAQ more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSAQ vs. The Competition

Health Sciences Acquisitions Co. 2 Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools